Results 111 to 120 of about 704 (128)

Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients. [PDF]

Clin Interv Aging
Liu T, Li Z, Wei G, Yang Y, Wang F, Wang Y, Kang K, Yang P, Li H, Liu B, Fang X.   +10 more
europepmc   +1 more source

Advancing the chemotherapy of tuberculous meningitis: a consensus view. [PDF]

Lancet Infect Dis
Wasserman S, Donovan J, Kestelyn E, Watson JA, Aarnoutse RE, Barnacle JR, Boulware DR, Chow FC, Cresswell FV, Davis AG, Dooley KE, Figaji AA, Gibb DM, Huynh J, Imran D, Marais S, Meya DB, Misra UK, Modi M, Raberahona M, Ganiem AR, Rohlwink UK, Ruslami R, Seddon JA, Skolimowska KH, Solomons RS, Stek CJ, Thuong NTT, van Crevel R, Whitaker C, Thwaites GE, Wilkinson RJ.   +31 more
europepmc   +1 more source

Facile Synthesis of Oxazolidinones as Potential Antibacterial Agents. [PDF]

ChemistryOpen
Els SP, Govender KB, Sokhela MK, Bhatt N, Reddy N, Kruger HG, Arvidsson PI, Gunosewoyo H, Govender T, Naicker T.   +9 more
europepmc   +1 more source

Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems. [PDF]

Pharmaceutics
Elbehiry A, Marzouk E, Abalkhail A.
europepmc   +1 more source

Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates

European Journal of Pharmaceutical Sciences, 2020
Non-human primates (NHP) are thought to be a good preclinical animal model for tuberculosis because they develop disease characteristics that are similar to humans. The objective of the current study was to determine if NHPs can also be used to reliably predict the exposure of tedizolid, sutezolid, and its biologically active metabolite sutezolid-M1 in
Sarah Kim, Charles A Scanga, Véronique A Dartois   +2 more
exaly   +4 more sources

The synthesis of sutezolid and eperezolid using proline catalyzed α-aminoxylation of an aldehyde

Journal of Chemical Sciences, 2022
Gautham G Shenoy
exaly   +3 more sources

Sutezolid. Oxazolidinone antibacterial, treatment of tuberculosis

Drugs of the Future, 2013
Jean‐Philippe Lanoix, Eric L. Nuermberger   +1 more
exaly   +4 more sources

Spectroscopic identification of intermediates and final products of the chiral pool synthesis of sutezolid

Journal of Molecular Structure, 2020
Abstract Sutezolid is a new oxazolidinone derivative currently in clinical trials to determine its safety and efficacy towards highly drug-resistant tuberculosis. The aim of the study was the spectroscopic identification of selected key intermediate products of the chiral pool synthesis of sutezolid: (S1) (4-(2-fluoro-4-nitrophenyl)thiomorpholine ...
Katarzyna Michalska, Kornelia Lewandowska, Mikołaj ł Mizera   +2 more
exaly   +3 more sources

Characterization of degradation products and process-related impurity of sutezolid by liquid chromatography/electrospray ionization tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis, 2019
Sutezolid was a new oxazolidinone compound used for the treatment of M. tuberculosis. This study describes the separation, characterization and in silico toxicity prediction of three degradation products and one process-related impurity of sutezolid.
Kaijing Guo, Tingting Zhang, Yanan Wang, Bo Jin, Chen Ma   +4 more
exaly   +4 more sources